



European Monitoring Centre
for Drugs and Drug Addiction

PROGRAMME

4th Reitox week

23–27 November 2015
Lisbon

International cooperation coordination meetings

Monday 23 November 2015

EMCDDA building, Praça Europa 1, Cais do Sodré

09.30	<p>Coordination meeting with candidate and potential candidate countries (Albania, Bosnia and Herzegovina, Former Yugoslav Republic of Macedonia, Kosovo*, Montenegro and Serbia)</p> <p>Chairs: Cécile Martel and Gonçalo Felgueiras</p> <p>Room PAL102</p> <p>a. Opening and welcome address b. IPA 5 technical cooperation project</p>
12.30	Lunch break
14.00	<p>Coordination meeting with European neighbouring partner countries (Armenia, Azerbaijan, Georgia, Israel, Moldova, Morocco, Ukraine)</p> <p>Chairs: Cécile Martel and Gonçalo Felgueiras</p> <p>Room PAL102</p> <p>a. Opening and welcome address b. ENP technical cooperation project</p>
Interpretation will be provided in Russian/English/Russian during this coordination meeting	

Women and drugs — extended Reitox network meeting

Tuesday 24 November 2015

EMCDDA building, Praça Europa 1, Cais do Sodré

09.00	<p>Opening and welcome address by Wolfgang Götz</p> <p>Session I: Women and drug use Chairs: Cécile Martel and Paul Griffiths, EMCDDA <i>Commentator: Joakim Strandberg, Sweden</i></p> <p>Welcome address — Alexis Goosdeel, EMCDDA</p> <p>a. Overview of gender-related data on drug use in the EU — Linda Montanari, EMCDDA b. Executive women under the influence: gender differences in drug use in France, a matter of social status? — François Beck, France c. Is research on drug-related problems applicable to women? — Marica Ferri, EMCDDA d. Questions and discussion</p>
11.00	Coffee break
11.30	<p>Session II: Women and drug treatment Chairs: Martta Forsell, Finland and Linda Montanari, EMCDDA <i>Commentator: Aleksandar Tomcuk, Montenegro</i></p> <p>a. The gender dimension of prescription drug use and non medical use of prescription drugs in Europe and the Mediterranean — Marilyn Clark, Malta with commentary by Elisabetta Simeoni, Italy b. Pregnancy, treatment, OST debate: what's new about women using drugs? — Edle Ravndal, Norway c. Malva Project: women, drugs and violence. A specific approach in prevention and treatment — Mercè Martí, Malva Project, Spain d. Questions and discussion</p>
13.00	Lunch break
14.00	<p>Session III: Women and harm reduction Chairs: Marion Weigl, Austria and Ilze Jekabsone, EMCDDA <i>Commentator: Fatima Elomari, Morocco</i></p> <p>a. Challenges for access to drug and HIV treatment for women using drugs — Anda Kivite, Latvia b. Integrating gender specific services to harm reduction programmes: situation and way forward in the MENA Region — Elie Aaraj, Lebanon c. Questions and discussion</p>
15.30	Coffee break
16.00	<p>Session IV: Implications for monitoring and practice Chairs: Marica Ferri and Jane Mounteney, EMCDDA Panel discussion</p> <p>Conclusions of the meeting Cécile Martel and Alexis Goosdeel</p>
18.00	Cocktail

Interpretation will be provided in Russian/English/Russian

53rd Reitox network meeting

Wednesday 25 November 2015

Perspectives and new developments

Conference Centre, Praça Europa, Cais do Sodré

09.00	Pre-Reitox meeting (agenda to be provided by the Reitox Spokesperson)
13.00	Lunch break
14.00	<p>Plenary session I: Introduction and welcome address Chair: Alexis Goosdeel</p> <ul style="list-style-type: none"> a. Adoption of draft conclusions from previous meeting (June 2015) b. Follow-up of decisions taken during previous meeting c. Report from the pre-Reitox meeting by the Reitox Spokesperson d. Adoption of the final agenda <p>Plenary session II: Strategic overview for 2016–25 Chair: Alexis Goosdeel</p> <ul style="list-style-type: none"> a. General outline of a long-term strategy for the EMCDDA b. Possible budgetary perspectives and impact on EMCDDA and Reitox NFPs c. Roundtable and open discussion
15.30	Coffee break
16.00	<p>Plenary session III: Monitoring epidemiological key indicators Chair: Paul Griffiths</p> <ul style="list-style-type: none"> a. Presentation on the Spanish monitoring system during the last 20 years b. Conclusions from the EMCDDA 20 years of monitoring conference c. Assessment of the implementation of the five key indicators in Europe — state of progress and perspectives for the future d. General discussion e. Way forward
17.30	End of the day

Thursday 26 November 2015

Work programme and guidelines

Conference Centre, Praça Europa, Cais do Sodré

09.00	Parallel sessions I: 2016 national reporting package		
	Group 1: Drugs	Group 2: Treatment	Group 3: Harms and harm reduction
10.30	Coffee break		
11.00	Parallel sessions II: 2016 national reporting package		
	Group 1: Web surveys project in the framework of market size estimation	Group 2: Pre-filled workbooks — Research and Best practice	Group 3: Other voluntary workbooks
12.30	Lunch break		

14.00	Parallel sessions III: 2016 projects
	Group 1: Experts ratings Group 2: Outputs from the workbooks at national level
15.30	Coffee break
16.00	Plenary session IV: 2016 national reporting package Chair: Gonçalo Felgueiras
	<ul style="list-style-type: none"> a. Reporting from the parallel sessions b. Workbook processes and way forward c. Update on the revision of the SQ 25–26 prevention d. Adoption of the 2016 reporting package
20.00	Dinner at Páteo Alfacinha

Friday 27 November 2015**Reitox development strategy**

Conference Centre, Praça Europa, Cais do Sodré

09.00	Plenary session V: The Reitox Accreditation System Chair: Alexis Goosdeel
	<ul style="list-style-type: none"> a. Outline of the Accreditation System b. Timeline to implement the system c. Open discussion and way forward
	Plenary session VI: National monitoring systems — possible future developments Chair: tbc
	<ul style="list-style-type: none"> a. State of play of priorities and challenges at national level b. EU Health Indicators: recent developments and potential impact on monitoring c. Open discussion and way forward
	Plenary session VII: Project Factory Chair: Frédéric Denecker
	<ul style="list-style-type: none"> a. Horizontal cooperation projects among Reitox NFPs b. Update on current and future EC research projects c. Open discussion and way forward
11.30	Plenary session VIII: Conclusions Chair: Alexis Goosdeel
12.00	End of the meeting